Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
BOSTON, Feb. 05, 2016 -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced it will participate in multiple panel discussions at the 4th Annual Bloomberg Intelligence Healthcare Event on Friday, Feb. 12. The panels will begin at 1:30 pm ET and focus on the evolving strategies for biosimilars, as well as provide legal and regulatory updates on biosimilars.
The conference will be held on Friday, Feb. 12 starting at 8:30 am ET in New York City. Additional information is available at http://b.bloomberg.com/BIHealthCare-regsa. The link to the live audio webcast and replay of the presentation will be available through Bloomberg terminals at Live <go>.
About EPIRUS Biopharmaceuticals
EPIRUS Biopharmaceuticals (Nasdaq:EPRS) is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs). EPIRUS’ goal is to improve global patient access to important, cost-effective medicines. EPIRUS' current pipeline of biosimilar product candidates includes: BOW015 (infliximab, reference biologic Remicade®); BOW050 (adalimumab, reference biologic Humira®); BOW070 (tocilizumab, reference biologic Actemra®); BOW080 (eculizumab, reference biologic Soliris®); BOW090 (ustekinumab, reference biologic STELARA®); and BOW100 (golimumab, reference biologic SIMPONI®)i. The reference products for these candidates together generated approximately $29.2 billion in global sales for 2014, according to EvaluatePharma®. EPIRUS has established multiple partnerships to support its regulatory and commercialization efforts in global markets. For more information visit EPIRUS’ website at www.epirusbiopharma.com.
i Remicade is a registered trademark of Johnson and Johnson (www.jnj.com); Humira is a registered trademark of AbbVie (www.abbvie.com); Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group (www.gene.com); Stelara is owned and marketed by Centocor Ortho Biotech Inc, a wholly owned subsidiary of Johnson and Johnson (www.jnj.com); Simponi is marketed by Janssen Biotech Inc (www.janssenbiotech.com); Soliris is a registered trademark of Alexion Pharmaceuticals, Inc. (www.alxn.com)
Contact Information: For media inquiries: Hope Buggey, FleishmanHillard +1-919-336-3786 [email protected] For investor inquiries: Marek Ciszewski, J.D., EPIRUS Biopharmaceuticals +1-617-553-9716 [email protected]
